Dear SMA community,

One year ago we launched a global Managed Access Program (MAP), the first for a one-time gene therapy, to make Zolgensma^® (onasemnogene abeparvovec) available to eligible patients with spinal muscular atrophy (SMA) who are under the age of two in countries where Zolgensma has not received regulatory approval. Today we are pleased to share that we allocated 100 doses free-of-charge in 2020, and …